Capricor Therapeutics Presents New Data From Ongoing HOPE-3 OLE Study For Its Lead Asset, Deramiocel, For Treatment Of Upper Limb Impairment In DMD, At 31st Annual Congress Of WMS In Hiroshima
-24-Month Crossover Analysis: Patients Starting Deramiocel After a Year on Placebo Slowed Upper Limb Decline by 76% Compared with Their Own Prior Year--At 24 Months, Both Groups Showed Slower Decline in Upper Limb
Capricor's new medicine Deramiocel showed it slowed arm weakness in DMD patients significantly. When watching this stock, look for whether the medicine keeps working safely over time.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.